

**Statement under Regulation 13(3) of SEBI (Listing Obligation  
and Disclosure Requirements) Regulations, 2015, for the  
Quarter ended on 31<sup>st</sup> March, 2016**

Particulars	31/03/2016
<b>Investors' Complaints</b>	
Pending at the beginning of the quarter	NIL
Received during the quarter	12
Disposed of during the quarter	12
Remaining unsolved at the end of the quarter	NIL

For Jenburkt Pharmaceuticals Limited

  
Ashish R. Shah  
(Company Secretary)